CU23002A1 - Método de obtención de agregados antigénicos y su uso en formulaciones - Google Patents

Método de obtención de agregados antigénicos y su uso en formulaciones

Info

Publication number
CU23002A1
CU23002A1 CU20000279A CU20000279A CU23002A1 CU 23002 A1 CU23002 A1 CU 23002A1 CU 20000279 A CU20000279 A CU 20000279A CU 20000279 A CU20000279 A CU 20000279A CU 23002 A1 CU23002 A1 CU 23002A1
Authority
CU
Cuba
Prior art keywords
structures
resulting
formulations
aggregation
antigenic
Prior art date
Application number
CU20000279A
Other languages
English (en)
Inventor
Bernard Iloki Assanga Simon
Mensies Minerva Sewer
Dina Tleugabulova
Ricondo Luis Javier Cruz
Rubido Julio Cesar Aguilar
Nieto Gerardo Enrique Guillen
Gonzalez Verena Lucila Muzio
Arias Eduardo Penton
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20000279A priority Critical patent/CU23002A1/es
Priority to US10/433,492 priority patent/US20040202676A1/en
Priority to DE60141978T priority patent/DE60141978D1/de
Priority to AU2002221518A priority patent/AU2002221518B2/en
Priority to PT01998363T priority patent/PT1346727E/pt
Priority to PCT/CU2001/000009 priority patent/WO2002043756A2/es
Priority to AU2151802A priority patent/AU2151802A/xx
Priority to ARP010105554A priority patent/AR031437A1/es
Priority to BR0115859-7 priority patent/BRPI0115859B8/pt
Priority to JP2002545726A priority patent/JP4974441B2/ja
Priority to RU2003119455/13A priority patent/RU2266754C2/ru
Priority to ES01998363T priority patent/ES2342150T3/es
Priority to CNB018198236A priority patent/CN1253206C/zh
Priority to AT01998363T priority patent/ATE465752T1/de
Priority to CA2429543A priority patent/CA2429543C/en
Priority to EP01998363A priority patent/EP1346727B1/en
Priority to KR1020037007094A priority patent/KR100873675B1/ko
Priority to ZA200303948A priority patent/ZA200303948B/en
Publication of CU23002A1 publication Critical patent/CU23002A1/es
Priority to US11/870,088 priority patent/US20090104223A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con el método para la obtención de estructuras antigénicas de naturaleza agregada, capaces de potenciar la respuesta inmune a antígenos agregados administrados por vía sistémica y/o mucosal, generando potentes respuestas inmunes así coma estructuras químicas resultantes de la aplicación de este método, formulaciones obtenidas a partir de dichas estructuras y uso de las mismas. El método describe la obtención de nuevas estructuras antigénicas agregadas a partir del uso de agentes o compuestos agregantes, delipidantes u oxidantes que permiten la liberación de lípidos de la partícula y la agregación de las mismas de forma heterogénea, seleccionándose posteriormente agregados de partículas de tallas entre 30 y 500 nm mediante un proceso de exclusión molecular. También se puede provocar el estado de agregación en el interior de la levadura variando las condiciones de incubación. Las estructuras resultantes pueden utilizarse convenientemente adyuvadas o en una formulación donde pueden introducirse varios antígenos, encontrándose un efecto sinérgico entre estos componentes con respecto a la inmunogenicidad de la respuesta obtenida. Además la preparación puede contener, estabilizadores y preservos. Las estructuras antigénicas resultantes son aplicables en la industria farmacéutica como formulaciones vacunales preventivas o terapéuticas tanto para el uso humano como veterinario y como parte de sistemas de diagnóstico.
CU20000279A 2000-12-01 2000-12-01 Método de obtención de agregados antigénicos y su uso en formulaciones CU23002A1 (es)

Priority Applications (19)

Application Number Priority Date Filing Date Title
CU20000279A CU23002A1 (es) 2000-12-01 2000-12-01 Método de obtención de agregados antigénicos y su uso en formulaciones
JP2002545726A JP4974441B2 (ja) 2000-12-01 2001-11-29 抗原性凝集物を得る方法と製剤におけるその使用
RU2003119455/13A RU2266754C2 (ru) 2000-12-01 2001-11-29 Способ получения антигенных агрегатов и их применение в препаратах
AU2002221518A AU2002221518B2 (en) 2000-12-01 2001-11-29 Method for obtaining antigenic aggregates and the use thereof in formulations
PT01998363T PT1346727E (pt) 2000-12-01 2001-11-29 Método para a obtenção de agregados antigénicos e a sua utilização em formulações
PCT/CU2001/000009 WO2002043756A2 (es) 2000-12-01 2001-11-29 Método de obtención de agregados antigénicos y su uso en formulaciones
AU2151802A AU2151802A (en) 2000-12-01 2001-11-29 Method for obtaining antigenic aggregates and the use thereof in formulations
ARP010105554A AR031437A1 (es) 2000-12-01 2001-11-29 Metodo de obtencion de agregados antigenicos y su uso en formulaciones
BR0115859-7 BRPI0115859B8 (pt) 2000-12-01 2001-11-29 método de obtenção de estruturas antigênicas agregadas de alta imunogenicidade, estrutura antigênica agregada, formulação de vacina e usos de uma estrutura antigênica e de formulações de vacina
US10/433,492 US20040202676A1 (en) 2000-12-01 2001-11-29 Method for obtaining antigenic aggregates and the use thereof in formulations
DE60141978T DE60141978D1 (de) 2000-12-01 2001-11-29 Verfahren zur gewinnung delipidierter antigener aggregate von hepatitis b und deren verwendung
ES01998363T ES2342150T3 (es) 2000-12-01 2001-11-29 Procedimiento de obtencion de agregados antigenicos de la hepatitis b deslipidados y uso de los mismos.
CNB018198236A CN1253206C (zh) 2000-12-01 2001-11-29 获得抗原性聚集物的方法及其在制剂中的用途
AT01998363T ATE465752T1 (de) 2000-12-01 2001-11-29 Verfahren zur gewinnung delipidierter antigener aggregate von hepatitis b und deren verwendung
CA2429543A CA2429543C (en) 2000-12-01 2001-11-29 Method for obtaining antigenic aggregates and the use thereof in formulations
EP01998363A EP1346727B1 (en) 2000-12-01 2001-11-29 Method for obtaining delipidated hepatitis b antigenic aggregates and their use thereof
KR1020037007094A KR100873675B1 (ko) 2000-12-01 2001-11-29 항원응집체의 수득방법 및 제제에서의 이의 용도
ZA200303948A ZA200303948B (en) 2000-12-01 2003-05-21 Method for obtaining antigenic aggregates and the use thereof in formulations.
US11/870,088 US20090104223A1 (en) 2000-12-01 2007-10-10 Method for Obtaining Antigenic Aggregates and the Use Thereof in Formulations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20000279A CU23002A1 (es) 2000-12-01 2000-12-01 Método de obtención de agregados antigénicos y su uso en formulaciones

Publications (1)

Publication Number Publication Date
CU23002A1 true CU23002A1 (es) 2004-11-18

Family

ID=5459569

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20000279A CU23002A1 (es) 2000-12-01 2000-12-01 Método de obtención de agregados antigénicos y su uso en formulaciones

Country Status (17)

Country Link
US (2) US20040202676A1 (es)
EP (1) EP1346727B1 (es)
JP (1) JP4974441B2 (es)
KR (1) KR100873675B1 (es)
CN (1) CN1253206C (es)
AR (1) AR031437A1 (es)
AT (1) ATE465752T1 (es)
AU (2) AU2002221518B2 (es)
BR (1) BRPI0115859B8 (es)
CA (1) CA2429543C (es)
CU (1) CU23002A1 (es)
DE (1) DE60141978D1 (es)
ES (1) ES2342150T3 (es)
PT (1) PT1346727E (es)
RU (1) RU2266754C2 (es)
WO (1) WO2002043756A2 (es)
ZA (1) ZA200303948B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23405A1 (es) * 2003-10-20 2009-08-04 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas para uso terapéutico
EP1652914A1 (en) * 2004-10-27 2006-05-03 Berna Biotech AG Virosome particles comprising antigens from influenza virus and Hepatitis B virus
PL1802746T3 (pl) * 2004-10-27 2011-10-31 Crucell Switzerland Ag Cząstki wirosomu zawierające antygeny wirusa grypy i wirusa zapalenia wątroby typu B
US7361360B2 (en) * 2005-07-27 2008-04-22 Lipid Sciences, Inc. Method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response
CU23740A1 (es) * 2009-09-29 2011-12-28 Ct Ingenieria Genetica Biotech Método de obtención de una formulación de antígenos del virus de la hepatitis b
AR107262A1 (es) 2016-01-27 2018-04-11 Lilly Co Eli Inactivación de patógenos por delipidación
CN109219449B (zh) * 2016-03-31 2022-08-30 遗传工程与生物技术中心 包含乙型肝炎病毒的表面抗原和核衣壳抗原的药用组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8421282D0 (en) * 1984-08-22 1984-09-26 Connaught Lab Multispecific antigenic proteins
ES2039229T3 (es) 1986-01-14 1993-09-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos.
US5728804A (en) * 1995-06-02 1998-03-17 Research Corporation Technologies, Inc. Use of cyclodextrins for protein renaturation
ES2260235T3 (es) * 2000-06-22 2006-11-01 Ucb Pharma Limited Modificacion del antigeno "core" de la hepatitis b.
US8092734B2 (en) * 2004-05-13 2012-01-10 Aptina Imaging Corporation Covers for microelectronic imagers and methods for wafer-level packaging of microelectronics imagers

Also Published As

Publication number Publication date
WO2002043756A3 (es) 2003-01-09
JP2004529861A (ja) 2004-09-30
JP4974441B2 (ja) 2012-07-11
AU2151802A (en) 2002-06-11
KR20030068161A (ko) 2003-08-19
BRPI0115859B1 (pt) 2020-10-13
PT1346727E (pt) 2010-05-21
WO2002043756A2 (es) 2002-06-06
CA2429543C (en) 2012-07-10
ATE465752T1 (de) 2010-05-15
ES2342150T3 (es) 2010-07-02
EP1346727B1 (en) 2010-04-28
KR100873675B1 (ko) 2008-12-11
AR031437A1 (es) 2003-09-24
CA2429543A1 (en) 2003-05-20
CN1253206C (zh) 2006-04-26
DE60141978D1 (de) 2010-06-10
ZA200303948B (en) 2004-03-30
BRPI0115859B8 (pt) 2021-05-25
RU2266754C2 (ru) 2005-12-27
EP1346727A2 (en) 2003-09-24
US20090104223A1 (en) 2009-04-23
US20040202676A1 (en) 2004-10-14
CN1477972A (zh) 2004-02-25
AU2002221518B2 (en) 2006-06-01
BR0115859A (pt) 2003-12-30

Similar Documents

Publication Publication Date Title
DE60121136T2 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
Sawaengsak et al. Chitosan nanoparticle encapsulated hemagglutinin-split influenza virus mucosal vaccine
RU2349342C2 (ru) Менингококковые вакцины для введения через слизистую оболочку
US8642258B2 (en) Immunogenical complex formed by vaccinal antigens encapsulated by nanostructured mesoporous silica
Kang et al. Pluronic® F127 enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of Bordetella bronchiseptica antigens containing dermonecrotoxin
Goel et al. Cell mediated immune response after challenge in Omp25 liposome immunized mice contributes to protection against virulent Brucella abortus 544
ES2924988T3 (es) Composiciones con nanoemulsiones para prevenir, inhibir o eliminar una enfermedad alérgica e inflamatoria
Azuar et al. Cholic acid-based delivery system for vaccine candidates against group A streptococcus
JP2015038130A (ja) 結核のワクチンおよびその使用方法
CU23002A1 (es) Método de obtención de agregados antigénicos y su uso en formulaciones
JP5159322B2 (ja) ワクチンの有効性増強のためのアジュバント
Jones et al. Protollin™: a novel adjuvant for intranasal vaccines
AU2013239497B2 (en) Adjuvant
HU176180B (en) Process for preparing antigenic compositions
AU769390B2 (en) Vaccine composition
WO2015082465A1 (en) Swine vaccine against prrs and lawsonia intracellularis
AR031182A1 (es) Metodo de obtencion de estructuras antigenicas que potencian la reactividad cruzada especifica y su uso en formulaciones
US10420836B2 (en) Methods of immunizing a subject and compositions related thereto
US20150086587A1 (en) Vaccine adjuvant
Alam et al. Adjuvants in allergy: state of the art
AR038311A1 (es) Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
KR20220062345A (ko) 피내 투여용 복합 백신
Soni et al. Overview of Nanovaccines and Nanoadjuvants
Yang et al. Immune response effects of diverse vaccine antigen attachment ways based on the self-made nanoemulsion adjuvant in systemic MRSA infection
WO2018030338A1 (ja) アジュバント組成物